Company intelligence / Profile preview

CardiNor

Oslo, Norway

Ownership: Private
Development stage: Other

Overview

CardiNor has developed CE‑marked and research‑use‑only blood assays for the neuropeptide biomarker secretoneurin, which is an independent predictor of mortality in ventricular arrhythmia, acute heart failure and other cardiovascular conditions; products are commercially available with established distribution networks in Europe, the US, South America and Asia, now being integrated as a companion diagnostic into IC Targets’ planned Phase IIb trial of the MRI contrast agent mangafodipir for cardiac disease.[1][5][6]

Therapeutic areas: Cardiovascular
Modalities: Diagnostic assayIn vitro diagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

IC Targets (integration of secretoneurin testing with mangafodipir cardiac MRI program)[1]IBL-America (US distribution of research-use-only secretoneurin ELISA test)[6]

Beyond the preview

Go deeper on CardiNor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardiNor.

Explore the full profile